Inactive Instrument

Highlights Satsuma Pharmaceuticals, Inc.

Equities

STSA

US80405P1075

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Satsuma Pharmaceuticals, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration	Jan. 17	CI
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.	23-06-07	CI
Satsuma Pharmaceuticals' New Drug Application for Migraine Treatment Accepted for FDA Review	23-05-18	MT
Satsuma Pharmaceuticals, Inc. Announces FDA Acceptance of 505(b)(2) New Drug Application for STS101	23-05-18	CI
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals	23-04-18	MT
Satsuma Pharmaceuticals to be Acquired by Shin Nippon Biomedical	23-04-17	MT
Shin Nippon Biomedical Laboratories, Ltd. entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers for $27.6 million.	23-04-16	CI
Satsuma Pharmaceuticals Cash, Cash Equivalents and Marketable Securities Almost Halve to $52.5 Million at End of 2022	23-03-28	MT
SATSUMA PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-28	AQ
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-28	CI
Satsuma Pharmaceuticals, Inc. Provides an Update on Its STS101 Development Program and Corporate Update	22-12-20	CI
Satsuma Pharmaceuticals, Inc. Announces the Results of Phase 3 Clinical Studies for STS101	22-11-24	CI
ETF Preview: ETFs, Stock Futures Edge Lower Premarket Monday	22-11-14	MT
Satsuma Pharma's migraine drug fails late-stage study, shares crash	22-11-14	RE
Satsuma Pharmaceuticals Announces Topline Results from Summit Phase 3 Trial of STS101 for the Acute Treatment of Migraine	22-11-14	CI
SATSUMA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-03	AQ
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Satsuma Pharmaceuticals, Inc. Announces Positive Results from Ongoing STS101 ASCEND Phase 3 Open-Label, Long-Term Safety Trial	22-09-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Satsuma Pharmaceuticals, Inc.

Equities

STSA

US80405P1075

Highlights

Filters